Downregulation of miR-210-3p attenuates high glucose-induced angiogenesis of vascular endothelial cells via targeting FGFRL1

Research Article

Open Access Gateway Wen T. · Hong Y. · Cui Y. · Pan J. · Wang Y. · Luo Y.
Abstract

Introduction: Vascular endothelial cell injury and angiogenesis induced by hyperglycemia are the main pathological basis of vascular complications in diabetes mellitus. The purpose of our study was to investigate the role and mechanism of miR-210-3p on high glucose-induced angiogenesis. Methods: Human umbilical vein endothelial cells (HUVECs) were treated with high glucose (HG) to mimic the pathological process of hyperglycemia. HUVECs were divided into the Control group, HG group, HG+inhibitor-NC group, and HG+miR-210-3p inhibitor group. Proliferation and migration were tested by wound healing assay, tube formation, and Transwell assay. Quantitation real-time PCR and Western blots were performed to determine the expression of miR-210-3p and relative proteins, respectively. Results: The level of miR-210-3p significantly increased in HUVECs treated by HG. The knockdown of miR-210-3p attenuated the tube formation, proliferation, and migration of cultured HUVECs in vitro to inhibit angiogenesis by increasing the expression of fibroblast growth factor receptor-like 1 (FGFRL1) and then attenuating the phosphorylation of STAT3, ERK, and ATK. Conclusion: Our study revealed that miR-210-3p might be a promising target for the treatment of diabetic-associated vascular injury.

The Author(s). Published by S. Karger AG, Basel

 Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
View original article
OPHTHALMIC RESEARCH

留言 (0)

沒有登入
gif
format_indent_decrease